Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arbutus Biopharma Corp
(NQ:
ABUS
)
3.870
+0.040 (+1.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arbutus Biopharma Corp
< Previous
1
2
3
4
Next >
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters
March 18, 2022
Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,
Via
Benzinga
Arbutus Biopharma Earnings Perspective: Return On Capital Employed
March 09, 2022
Benzinga Pro data, Arbutus Biopharma (NASDAQ:ABUS) reported Q4 sales of $3.21 million. Earnings fell to a loss of $21.32 million, resulting in a 11.29% decrease from last quarter...
Via
Benzinga
Arbutus Biopharma: Q4 Earnings Insights
March 03, 2022
Arbutus Biopharma (NASDAQ:ABUS) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement....
Via
Benzinga
Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s)
February 28, 2022
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Genevant have sued Moderna Inc (NASDAQ: MRNA) for infringing on their patent on a lipid...
Via
Benzinga
Futures, Global Markets Soar In Biggest 4-Day Rally Since November 2020
February 02, 2022
US equity futures and global stocks from Europe to Asia were headed for the biggest four-day rally since November 2020, supercharged by blockbuster earnings AMD and Google, which hit an all time high...
Via
Talk Markets
Earnings Scheduled For March 3, 2022
March 03, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
February 02, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09...
Via
Benzinga
23 Stocks Moving in Wednesday's Pre-Market Session
February 02, 2022
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out: Executives buy more than $600 million of 3...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 31, 2022
Welcome back, trader! We're ready for another busy week of trading as we start it with the biggest pre-market stock movers for Monday!
Via
InvestorPlace
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
January 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura...
Via
Benzinga
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
December 29, 2021
Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current
Via
Talk Markets
25 Stocks Moving in Monday's Pre-Market Session
December 20, 2021
Gainers Society Pass Incorporated (NASDAQ: SOPA) rose 68% to $5.59 in pre-market trading after the company reported addition to the Russell 2000 Index. Verso Corporation (NYSE:...
Via
Benzinga
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board
December 18, 2021
BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai.
Via
Talk Markets
How Will Moderna Stock Weather Omicron? — And Other Questions Clouding 2022
December 16, 2021
Analysts call for a sales and earnings decline in 2022. Can Moderna stave it off?
Via
Investor's Business Daily
Why Arbutus Biopharma Shares Are Rising
December 13, 2021
Arbutus Biopharma Corp (NASDAQ: ABUS) shares are trading higher after the company announced it received a $40M upfront payment from Qilu to commercialize AB-729 in Asia...
Via
Benzinga
Arbutus Biopharma Shares Jump After Achieving First Milestone Under COVID-19 Pact
December 07, 2021
Arbutus Biopharma Corporation (NASDAQ: ABUS) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating...
Via
Benzinga
Exposures
COVID-19
20 Stocks Moving in Friday's Pre-Market Session
December 03, 2021
Gainers BIOLASE, Inc. (NASDAQ: BIOL) rose 27.2% to $0.52 in pre-market trading. Biolase reporte in Form4 filing that President bought 70,000 shares at an average price of $0.45...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
December 02, 2021
Good morning, trader! We're gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday!
Via
InvestorPlace
27 Stocks Moving in Thursday's Pre-Market Session
December 02, 2021
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 25.8% to $4.09 in pre-market trading after surging around 12% on Wednesday. Digital World Acquisition Corp. (NASDAQ: DWAC)...
Via
Benzinga
61 Biggest Movers From Yesterday
December 02, 2021
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Why Moderna Stock Plunged Today
December 01, 2021
A patent dispute could pressure the vaccine maker's profits.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Mid-Afternoon Market Update: Dow Rises Over 100 Points; CTI BioPharma Shares Plummet
December 01, 2021
Toward the end of trading Wednesday, the Dow traded up 0.39% to 34,617.2 while the NASDAQ climbed 0.17% to 15,564.73. The S&P also rose, gaining 0.68% to 4,597.96. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Arbutus' Hepatitis B Candidate Shows Encouraging Antiviral Activity
December 01, 2021
Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced preliminary data from its Phase 1a/1b trial of AB-836, an oral hepatitis B virus (HBV) capsid inhibitor...
Via
Benzinga
ABUS Stock Alert: The Moderna News That Has Arbutus Biopharma Shares Rocketing Today
December 01, 2021
Arbutus Biopharma (ABUS) stock is taking off on Wednesday thanks to a court ruling in its favor in a case against Moderna (MRNA).
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
Why Arbutus Shares Are Soaring Today
December 01, 2021
Arbutus Biopharma Corp (NASDAQ: ABUS) is soaring Wednesday after The Patent Trial and Appeals Board turned down Moderna Inc's (NASDAQ: MRNA) appeal to...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Mid-Day Market Update: Build-A-Bear Jumps After Q3 Results; BeyondSpring Shares Slide
December 01, 2021
Midway through trading Wednesday, the Dow traded up 1.06% to 34,847.76 while the NASDAQ climbed 1.17% to 15,719.00. The S&P also rose, gaining 1.48% to 4,634.64. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
50 Stocks Moving In Wednesday's Mid-Day Session
December 01, 2021
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Why Arbutus Biopharma Is Rocketing Higher Today
December 01, 2021
A recent court of appeals decision is bad news for Moderna and great news for Arbutus Biopharma.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
Why Moderna Shares Are Sliding Today
December 01, 2021
Moderna Inc (NASDAQ: MRNA) is trading lower Wednesday after The Patent Trial and Appeals Board turned down the company's appeal to invalidate two of Arbutus Biopharma...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Arbutus Shares Are Soaring As Moderna Loses Appeal Of Board Ruling On COVID-19 Vaccine Delivery Technology Patent
December 01, 2021
Shares of small-cap biotech Arbutus Biopharma Corporation (NASDAQ: ABUS) are advancing strongly on above-average volume on Wednesday. What Happened: The Patent Trial and Appeals...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.